Fanfare marks Novartis' move to new UK home

11 February 2020
vas_narasimhan_marie_france_tschudin_matt_hancock_haseeb_ahmad_novartis_large

Big names from the government and life sciences, as well as top brass from Novartis (NOVN: VX), were in attendance as the Swiss pharma giant marked the official opening of its new UK headquarters.

Novartis has focused communications around the opening of the new site in White City, west London, on its launch of a new UK-centered clinical trial of the cardiovascular candidate inclisiran, which the company acquired in its $9.7 billion buy of The Medicines Company last year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical